Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × OTHER × pCR Rate × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1877 Carcinoma, Non-Small-Cell Lung 1336 Prostatic Neoplasms 973 Colorectal Neoplasms 836 Multiple Myeloma 738 Leukemia, Myeloid, Acute 714 Neoplasms 687 Lung Neoplasms 674 Neoplasm Metastasis 638 Lymphoma 573 Pancreatic Neoplasms 564 Carcinoma, Hepatocellular 564 Stomach Neoplasms 518 Leukemia 511 Recurrence 486 Leukemia, Lymphocytic, Chronic, B-Cell 457 Precursor Cell Lymphoblastic Leukemia-Lymphoma 450 Melanoma 450 Lymphoma, Non-Hodgkin 440 Ovarian Neoplasms 424 Lymphoma, Large B-Cell, Diffuse 418 Myelodysplastic Syndromes 414 Squamous Cell Carcinoma of Head and Neck 409 Brain Neoplasms 402 Head and Neck Neoplasms 400 Rectal Neoplasms 390 Glioblastoma 371 Carcinoma, Renal Cell 343 Hodgkin Disease 335 Esophageal Neoplasms 334

Interventions

Metformin 1 Epirubicin 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01929811 2022-04-06

NeoMET

Shanghai Jiao Tong University School of Medicine

Phase 2 Terminated

pCR Rate

Data powered by HemOnc (CC BY 4.0) Colophon ⚡